On November 29, 2010, Intellipharmaceutics International, Inc. will have newly-appointed Shameze Rampertab stepping-in to serve as the company’s new Chief Financial Officer, replacing the recently resigned Graham Neil. Mr. Neil recently stepped-down to pursue other business opportunities.
Mr. Rampertab will be bringing a highly-relevant skill set with him to the Intellipharmaceutics’ team. A chartered accountant for nearly twenty years, he has senior-level executive experience in many aspects of biotechnology and related finance fields, including licensing and royalty agreements, through his previous positions at companies such as Drug Royalty Corporation, where he served as Director as well as Finance and Secretary-Treasurer. Additionally, Mr. Rampertab recently left his position as a Partner, specializing in raising equity funds for life science companies, at Loewen, Ondaatje, McCutcheon Limited, an investment banking firm focused on small and mid-capitalization companies providing advisory services in mergers and acquisitions and divestitures amongst other things.
Mr. Rampertab is a graduate of McMaster University in Hamilton, Ontario, Canada where he earned a BSc in molecular genetics and molecular biology in 19989 and his MBA in 1991. McMaster has been ranked as one of the Top 100 universities in the world, according to Shanghai Jiao Tong University’s ranking of world universities.
Intellipharmaceutics will be drawing upon Shameze’s experiences and knowledge as the Company continues to move forward with its patented Hypermatrix™ technology, a multi-dimensional controlled-release drug delivery platform formulated to improve a vast array of new and existing pharmaceuticals, as well as the other 15 compounds in the Intellipharmaceutics’ portfolio.
Toronto, Canada-based Intellipharmaceutics trades on the NASDAQ exchange under the ticker “IPCI” as well as the Toronto Stock Exchange under the ticker “I”. More information on the Company can be found on its corporate website at www.intellipharmaceutics.com.
Let us hear your thoughts below:
